13th edition

Format
HYBRID

December 3rd & 4th, 2024

IN-PERSON | LILLE, FR

December 11th& 12th 2024

ONLINE MEETINGS

Stand B6/1

2022 Edition

Temisis Therapeutics

fr

Founded in late 2017, Temisis is a biotechnology company focused on the discovery and development of novel small molecule compounds to treat inflammatory diseases with high unmet needs. TEM1657, our lead program has showed great efficacy in pre-clinical studies, both orally and topically, to relieve psoriasis symptoms without the side effects associated with existing treatments. TEM1657 unique efficacy and safety profile is explained by its first-in-class MoA, currently under investigation.

Scroll to Top
  • No products in the cart.